U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H25N3O3S
Molecular Weight 459.56
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOVERINE

SMILES

O=C(CN1CCN(CC2=CC3=C(OCO3)C=C2)CC1)N4C5=CC=CC=C5SC6=CC=CC=C46

InChI

InChIKey=UBAJTZKNDCEGKL-UHFFFAOYSA-N
InChI=1S/C26H25N3O3S/c30-26(29-20-5-1-3-7-24(20)33-25-8-4-2-6-21(25)29)17-28-13-11-27(12-14-28)16-19-9-10-22-23(15-19)32-18-31-22/h1-10,15H,11-14,16-18H2

HIDE SMILES / InChI
Molecular Formula C26H25N3O3S
Molecular Weight 459.56
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Fenoverine is a potent musculotropic, the anti-spasmodic agent that restores smooth muscle motility and relieves the distressing symptoms associated with irritable bowel syndrome (IBS) and primary dysmenorrhea. Fenoverine is a non-anticholinergic phenothiazine derivative that may also inhibit calcium channel currents. Fenoverine primarily affects the gastrointestinal tract, bile duct, and female genital organs. Fenoverine has been repeatedly implicated in the occurrence of rhabdomyolysis, a potentially fatal adverse effect, in France. Thes drug has been therefore unavailable in France since December 1995 but commonly used in the treatment of gastrointestinal spasmodic disorders in Taiwan.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
846
Blocker
555
 7.5 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010-12
In vitro evaluation of domperidone mouth dissolving tablets.
2010-11
Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine.
2010-03
Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants.
2007-11
Fenoverine vs. mefenamic acid in the treatment of primary dysmenorrhea.
2006-04
Rhabdomyolysis induced by fenoverine: a case report and literature review.
2005-09
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:24:06 GMT 2025
Edited
by admin
on Wed Apr 02 09:24:06 GMT 2025
Record UNII
N274ZQ6PZJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENOVERINE [MI]
Preferred Name English
FENOVERINE
INN   MART.   MI   USP-RS   WHO-DD  
INN  
Official Name English
10-((4-PIPERONYL-1-PIPERAZINYL)ACETYL)PHENOTHIAZINE
Systematic Name English
Fenoverine [WHO-DD]
Common Name English
fenoverine [INN]
Common Name English
FENOVERINE [MART.]
Common Name English
10-((4-(1,3-BENZODIOXOL-5-YLMETHYL)-1-PIPERAZINYL)ACETYL)-10H-PHENOTHIAZINE
Systematic Name English
SPASMOPRIV
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29698
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
WHO-ATC A03AX05
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
WHO-VATC QA03AX05
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
Code System Code Type Description
EVMPD
SUB07580MIG
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
WIKIPEDIA
FENOVERINE
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
SMS_ID
100000081302
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
MESH
C048314
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
DRUG CENTRAL
1156
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
CAS
37561-27-6
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
NCI_THESAURUS
C65660
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
ECHA (EC/EINECS)
253-552-1
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
RXCUI
24855
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY RxNorm
FDA UNII
N274ZQ6PZJ
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
ChEMBL
CHEMBL1512949
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
INN
3288
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
DRUG BANK
DB13042
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
PUBCHEM
72098
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
MERCK INDEX
m5283
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID8046296
Created by admin on Wed Apr 02 09:24:06 GMT 2025 , Edited by admin on Wed Apr 02 09:24:06 GMT 2025
PRIMARY
Related Record Type Details
Structure of FENOVERINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966